LUC00031I2 - - Google Patents

Info

Publication number
LUC00031I2
LUC00031I2 LU00031C LUC00031C LUC00031I2 LU C00031 I2 LUC00031 I2 LU C00031I2 LU 00031 C LU00031 C LU 00031C LU C00031 C LUC00031 C LU C00031C LU C00031 I2 LUC00031 I2 LU C00031I2
Authority
LU
Luxembourg
Application number
LU00031C
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of LUC00031I1 publication Critical patent/LUC00031I1/fr
Publication of LUC00031I2 publication Critical patent/LUC00031I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU00031C 2001-05-31 2017-08-09 LUC00031I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US34104801P 2001-12-06 2001-12-06
EP02733058A EP1392694A1 (fr) 2001-05-31 2002-05-29 Resolution optique de (1-benzyl-4-methylpiperidine-3-yle) methylamine et son utilisation pour la preparation de derives de pyrrolo 2,3-pyrimidine utilises comme inhibiteurs de proteines kinase

Publications (2)

Publication Number Publication Date
LUC00031I1 LUC00031I1 (fr) 2017-08-10
LUC00031I2 true LUC00031I2 (fr) 2017-10-11

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00031C LUC00031I2 (fr) 2001-05-31 2017-08-09

Country Status (52)

Country Link
US (2) US7301023B2 (fr)
EP (3) EP1666481B9 (fr)
JP (1) JP4381137B2 (fr)
KR (5) KR20060133117A (fr)
CN (1) CN1729192A (fr)
AP (1) AP1859A (fr)
AR (2) AR037321A1 (fr)
AT (1) ATE519741T1 (fr)
AU (2) AU2002304401C1 (fr)
BE (1) BE2017C032I2 (fr)
BG (1) BG66489B1 (fr)
BR (1) BR0209246A (fr)
CA (1) CA2448281C (fr)
CL (1) CL2008000762A1 (fr)
CR (1) CR10177A (fr)
CU (1) CU23337B7 (fr)
CY (2) CY1113322T1 (fr)
CZ (1) CZ304366B6 (fr)
DK (1) DK1666481T3 (fr)
EA (2) EA007251B1 (fr)
EC (1) ECSP034865A (fr)
EE (1) EE05332B1 (fr)
ES (2) ES2369226T3 (fr)
FR (1) FR17C1031I2 (fr)
GE (1) GEP20063784B (fr)
GT (2) GT200200100A (fr)
HR (1) HRP20030943B1 (fr)
HU (2) HU230876B1 (fr)
IL (1) IL158588A0 (fr)
IS (1) IS3023B (fr)
LT (1) LTC1666481I2 (fr)
LU (1) LUC00031I2 (fr)
MA (1) MA27029A1 (fr)
MX (1) MXPA03011062A (fr)
MY (1) MY129649A (fr)
NL (1) NL300887I2 (fr)
NO (3) NO328578B1 (fr)
NZ (2) NZ530380A (fr)
OA (1) OA12612A (fr)
PA (1) PA8546301A1 (fr)
PE (1) PE20030561A1 (fr)
PL (2) PL367945A1 (fr)
PT (1) PT1666481E (fr)
RS (1) RS52144B (fr)
SI (1) SI1666481T1 (fr)
SK (2) SK288199B6 (fr)
TN (1) TNSN03128A1 (fr)
TW (2) TWI316061B (fr)
UA (1) UA80093C2 (fr)
UY (1) UY27317A1 (fr)
WO (1) WO2002096909A1 (fr)
ZA (1) ZA200307982B (fr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
KR100477818B1 (ko) 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-d] 피리미딘 화합물
PT1294724E (pt) * 2000-06-26 2006-07-31 Pfizer Prod Inc Compostos pirrolo (2,3-d ) pirimidina como agentes imunosupressivos
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
US7476683B2 (en) * 2002-08-27 2009-01-13 Merck Patent Gmbh Glycinamide derivatives as raf-kinase inhibitors
JP2006509000A (ja) 2002-11-26 2006-03-16 ファイザー・プロダクツ・インク 移植片拒絶反応の処置の方法
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
JP2007536310A (ja) * 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト S1p受容体アゴニストおよびjak3キナーゼ阻害剤を含む、組合せ剤
WO2006004703A2 (fr) 2004-06-29 2006-01-12 Amgen Inc. Pyrrolo [2, 3-d] pyrimidines qui modulent l'activite ack1 et lck
US7465726B2 (en) 2004-08-02 2008-12-16 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2.3-B]pyridines
US20090156602A1 (en) * 2004-11-24 2009-06-18 Nigel Graham Cooke Organic Compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006133426A2 (fr) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions et procedes d'inhibition de la voie jak
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ3阻害剤
EP2251341A1 (fr) 2005-07-14 2010-11-17 Astellas Pharma Inc. Hétérocycles inhibiteurs de Janus kinase-3
AU2006273762A1 (en) 2005-07-29 2007-02-01 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
CA2621261C (fr) 2005-09-22 2014-05-20 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
UA98449C2 (en) 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CN101743009A (zh) * 2007-07-11 2010-06-16 辉瑞大药厂 治疗干眼病的药物组合物和方法
LT2265607T (lt) 2008-02-15 2017-03-27 Rigel Pharmaceuticals, Inc. Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių
JP5275371B2 (ja) 2008-03-11 2013-08-28 インサイト・コーポレイション Jak阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
NZ590922A (en) * 2008-08-01 2012-09-28 Biocryst Pharm Inc Piperidine derivatives as jak3 inhibitors
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
WO2010093808A1 (fr) * 2009-02-11 2010-08-19 Reaction Biology Corp. Inhibiteurs de kinase sélectifs
EP2421867B1 (fr) * 2009-04-20 2015-09-02 Auspex Pharmaceuticals, Llc Inhibiteurs pipéridiniques de la janus kinase 3
LT2432472T (lt) 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
KR101481872B1 (ko) * 2009-09-10 2015-01-12 에프. 호프만-라 로슈 아게 Jak의 억제제
JP5946768B2 (ja) 2009-10-09 2016-07-06 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation 3−(4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピラゾール−1−イル)−3−シクロペンチルプロパンニトリルのヒドロキシル、ケト及びグルクロニド誘導体
EA201290147A1 (ru) 2009-10-15 2012-11-30 Пфайзер Инк. Пирроло[2,3-d]пиримидиновые соединения
ES2461967T3 (es) 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
TW201129565A (en) * 2010-01-12 2011-09-01 Hoffmann La Roche Tricyclic heterocyclic compounds, compositions and methods of use thereof
AU2011213198B2 (en) 2010-02-05 2014-04-24 Zoetis Llc Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
CN103002875B (zh) 2010-05-21 2016-05-04 因塞特控股公司 Jak抑制剂的局部用制剂
WO2012061428A2 (fr) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides en tant que modulateurs des jak kinases
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
EP2481397A1 (fr) 2011-01-27 2012-08-01 Ratiopharm GmbH Compositions pharmaceutiques comportant du tasocitinib
EP2481411A1 (fr) 2011-01-27 2012-08-01 Ratiopharm GmbH Formes galéniques orales pour libération modifiée comportant l'inhibiteur de JAK3 tasocitinib
CN103732226B (zh) 2011-02-18 2016-01-06 诺瓦提斯药物公司 mTOR/JAK抑制剂组合疗法
WO2012135338A1 (fr) 2011-03-28 2012-10-04 Ratiopharm Gmbh Procédés pour la préparation de sels de tofacitinib
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
CN104610264A (zh) * 2011-04-08 2015-05-13 辉瑞大药厂 结晶和非结晶形式的托法替尼,以及包含托法替尼和渗透增强剂的药物组合物
EP2524688B1 (fr) 2011-05-11 2013-05-01 ratiopharm GmbH Composition de libération modifiée comportant de la ranolazine
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
EP2741747A1 (fr) 2011-08-10 2014-06-18 Novartis Pharma AG Polythérapie par jak p13k/mtor
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
CA3131037A1 (fr) * 2011-11-30 2013-06-06 Emory University Inhibiteurs de jak antiviraux utiles dans le traitement ou la prevention d'infections retrovirales et autres infections virales
EP2791141B1 (fr) 2011-12-15 2017-02-08 ratiopharm GmbH Sel de mono-tartrate de Tofacitinib
WO2013173720A1 (fr) 2012-05-18 2013-11-21 Incyte Corporation Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak
CN104837817B (zh) 2012-07-25 2017-03-22 力奇制药公司 制备3‑氨基‑哌啶化合物的合成路线
WO2014058921A2 (fr) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Inhibiteurs substitués de pyrimidinyl kinase
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN104955803B (zh) * 2012-11-30 2017-11-28 斯洛文尼亚莱柯制药股份有限公司 通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
EP2935216B1 (fr) 2012-12-17 2018-06-27 Sun Pharmaceutical Industries Limited Procédé de préparation de tofacitinib et de ses intermédiaires
US9670160B2 (en) 2012-12-28 2017-06-06 Glenmark Pharmaceuticals Limited Process for the preparation of tofacitinib and intermediates thereof
AP2015008664A0 (en) 2013-02-22 2015-08-31 Pfizer Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK)
UA120162C2 (uk) 2013-03-06 2019-10-25 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014174073A1 (fr) 2013-04-26 2014-10-30 Sandoz Ag Formulations de tofacitinib à libération prolongée
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
CN104513248B (zh) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 一种托法替尼中间体的纯化方法
JP6192839B2 (ja) 2013-12-05 2017-09-06 ファイザー・インク ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、およびピロロ[2,3−d]ピリジニルアクリルアミド
HUE053975T2 (hu) * 2013-12-09 2021-08-30 Unichem Lab Ltd Továbbfejlesztett eljárás (3R,4R)-(1-benzil-4-metilpiperidin-3-il)-metilamin elõállítására
US9260438B2 (en) 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016024185A1 (fr) 2014-08-12 2016-02-18 Pfizer Inc. Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase
CN108349977B (zh) * 2015-01-20 2021-05-25 无锡福祈制药有限公司 Jak抑制剂
US10479763B2 (en) 2015-02-17 2019-11-19 Amorepacific Corporation Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives
CN104761556B (zh) * 2015-03-21 2017-06-23 河北国龙制药有限公司 托法替布中间体杂质、托法替布杂质及其合成方法,以及托法替布的质量监控方法
EP3078665A1 (fr) 2015-04-10 2016-10-12 OLON S.p.A. Procédé efficace pour la préparation de tofacitinib citrate
ES2734048T3 (es) 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidores de Janus cinasas (JAK)
ES2928757T3 (es) 2015-05-01 2022-11-22 Pfizer Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa
EA036063B1 (ru) 2015-05-29 2020-09-22 Уси Форчун Фармасьютикал Ко., Лтд Ингибитор янус-киназы
EP3328360A4 (fr) * 2015-07-27 2019-01-02 Unichem Laboratories Limited Comprimés à désintégration orale de tofacitinib
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
WO2017091681A1 (fr) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Inhibiteurs de kinase sélectifs
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20190083609A1 (en) 2016-01-18 2019-03-21 Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) Tofacitinib as vaccination immune modulator
JP2019519579A (ja) 2016-06-30 2019-07-11 デウン ファーマシューティカル カンパニー リミテッド キナーゼ阻害剤としてのピラゾロピリミジン誘導体
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko) 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
TN2020000082A1 (en) 2017-12-28 2022-01-06 Dae Woong Pharma Oxy-fluoropiperidine derivative as kinase inhibitor
KR20200129099A (ko) 2018-01-30 2020-11-17 인사이트 코포레이션 (1-(3-플루오로-2-(트리플루오로메틸)이소니코티닐)피페리딘-4-온)의 제조 방법
WO2019152232A1 (fr) * 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Formulations topiques comprenant du tofacitinib
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
KR102131107B1 (ko) * 2019-01-15 2020-07-07 주식회사 다산제약 3-아미노-피페리딘 화합물의 신규한 제조 방법
EP3938370A4 (fr) 2019-03-13 2022-12-21 Intas Pharmaceuticals Ltd. Procédé de préparation de tofacitinib et son sel pharmaceutiquement acceptable
WO2020198583A1 (fr) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Inhibiteurs de jak bicycliques et leurs utilisations
WO2020204647A1 (fr) * 2019-04-05 2020-10-08 Yuhan Corporation Procédés de préparation de (3r,4r)-1-benzyl-n,4-diméthylpipéridin-3-amine ou d'un sel de celui-ci et procédés de préparation de tofacitinib l'utilisant
KR20220101150A (ko) 2019-11-14 2022-07-19 화이자 인코포레이티드 1-(((2s,3s,4s)-3-에틸-4-플루오로-5-옥소피롤리딘-2-일)메톡시)-7-메톡시이소퀴놀린-6-카복사마이드 조합물 및 경구 투여 형태
EP4067354A4 (fr) 2019-11-25 2023-11-08 Daewoong Pharmaceutical Co., Ltd. Nouveau dérivé de triazolopyridine et composition pharmaceutique le comprenant
AU2021248720A1 (en) 2020-04-04 2022-11-03 Pfizer Inc. Methods of treating coronavirus disease 2019
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US20240166651A1 (en) * 2021-03-15 2024-05-23 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
EP4180042A1 (fr) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé enrobé d'un film comprenant du tofacitinib micronisé

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (nl) * 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JPH07330732A (ja) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd 光学活性な3−アミノ−1−ベンジルピペリジン誘導体
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
SK72996A3 (en) 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
MX9800136A (es) 1995-07-05 1998-03-29 Du Pont Pirimidinonas fungicidas.
CA2224435C (fr) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
PL321296A1 (en) 1995-11-14 1997-12-08 Pharmacia & Upjohn Spa Derivatives of aryl and heteroaryl purine
WO1997027199A1 (fr) 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US6207669B1 (en) 1996-07-13 2001-03-27 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0938486B1 (fr) 1996-08-23 2008-01-16 Novartis AG Pyrrolopyrimidines substituees et procede pour leur preparation
WO1998023613A1 (fr) 1996-11-27 1998-06-04 Pfizer Inc. Derives de pyrimidines bicycliques fusionnes
WO1998033798A2 (fr) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3d]pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
US6187552B1 (en) * 1997-03-24 2001-02-13 Pharmacia & Upjohn Company Method for identifying inhibitors of JAK2/cytokine receptor binding
JP2002510687A (ja) 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換ピロロ[2,3−b]ピリジンおよびピロロ[2,3−d]ピリミジン誘導体:crf1レセプタのモジュレータ
MXPA00011773A (es) 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolinas para tratar tumores en el cerebro.
JP4666762B2 (ja) * 1998-06-19 2011-04-06 ファイザー・プロダクツ・インク ピロロ[2.3−d]ピリミジン化合物
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2000000202A1 (fr) 1998-06-30 2000-01-06 Parker Hughes Institute Procede pour inhiber l'expression de c-jun en utilisant les inhibiteurs de jak-3
MXPA01001893A (es) 1998-08-21 2002-04-24 Parker Hughes Inst Derivados de quinazolina.
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
KR100477818B1 (ko) 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-d] 피리미딘 화합물
PT1294724E (pt) * 2000-06-26 2006-07-31 Pfizer Prod Inc Compostos pirrolo (2,3-d ) pirimidina como agentes imunosupressivos
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
WO2006004703A2 (fr) * 2004-06-29 2006-01-12 Amgen Inc. Pyrrolo [2, 3-d] pyrimidines qui modulent l'activite ack1 et lck

Also Published As

Publication number Publication date
ZA200307982B (en) 2004-10-14
FR17C1031I2 (fr) 2018-11-02
TW200413370A (en) 2004-08-01
DK1666481T3 (da) 2012-10-15
SK14652003A3 (sk) 2004-05-04
AU2008203170B2 (en) 2009-06-18
SI1666481T1 (sl) 2012-11-30
KR20080083028A (ko) 2008-09-12
CZ20033260A3 (en) 2004-03-17
ES2369226T3 (es) 2011-11-28
HRP20030943A2 (en) 2005-08-31
AU2002304401B2 (en) 2008-04-17
IS6993A (is) 2003-10-13
EP1666481B9 (fr) 2013-05-01
EP1609781A1 (fr) 2005-12-28
ES2393385T3 (es) 2012-12-20
UY27317A1 (es) 2003-02-28
EE200300594A (et) 2004-04-15
HRP20030943B1 (en) 2011-11-30
PT1666481E (pt) 2012-12-03
US20030073719A1 (en) 2003-04-17
NZ530380A (en) 2005-08-26
HUS1900008I1 (hu) 2020-02-28
KR100868814B1 (ko) 2008-11-14
NO2017047I1 (no) 2017-09-08
FR17C1031I1 (fr) 2017-10-13
US7432370B2 (en) 2008-10-07
YU92303A (sh) 2006-08-17
KR20040003037A (ko) 2004-01-07
EP1666481B1 (fr) 2012-09-19
EP1666481A3 (fr) 2006-11-29
EP1392694A1 (fr) 2004-03-03
NL300887I2 (nl) 2017-08-31
UA80093C2 (uk) 2007-08-27
TNSN03128A1 (fr) 2005-12-23
JP2004534047A (ja) 2004-11-11
BG108389A (bg) 2005-01-31
CL2008000762A1 (es) 2008-07-04
LTC1666481I2 (lt) 2018-06-25
CR10177A (es) 2008-08-19
AP2002002550A0 (en) 2002-06-30
AR045680A2 (es) 2005-11-09
CY1113322T1 (el) 2016-06-22
PL228155B1 (pl) 2018-02-28
KR20080002931A (ko) 2008-01-04
HUP0400152A3 (en) 2012-12-28
HUP0400152A2 (en) 2007-07-30
GT200200100A (es) 2003-02-11
EE05332B1 (et) 2010-08-16
SK288192B6 (sk) 2014-06-03
MXPA03011062A (es) 2004-03-19
NO20093135L (no) 2003-11-24
US20040229923A1 (en) 2004-11-18
SK288199B6 (sk) 2014-06-03
CN1729192A (zh) 2006-02-01
EP1666481A2 (fr) 2006-06-07
KR100869409B1 (ko) 2008-11-21
PE20030561A1 (es) 2003-06-23
CZ304366B6 (cs) 2014-04-02
CY2017028I2 (el) 2018-02-14
EA200600575A1 (ru) 2006-08-25
EP1609781B1 (fr) 2011-08-10
GEP20063784B (en) 2006-04-10
PL409305A1 (pl) 2014-12-22
BG66489B1 (bg) 2015-05-29
MY129649A (en) 2007-04-30
KR20060014459A (ko) 2006-02-15
GT200200100AA (es) 2007-07-06
PL367945A1 (en) 2005-03-07
IL158588A0 (en) 2004-05-12
ATE519741T1 (de) 2011-08-15
EA012666B1 (ru) 2009-12-30
NO20035201D0 (no) 2003-11-24
TWI316061B (en) 2009-10-21
AP1859A (en) 2008-07-02
IS3023B (is) 2020-08-15
CU23337B7 (es) 2009-01-20
BE2017C032I2 (fr) 2021-07-19
HU230876B1 (hu) 2018-11-29
CY2017028I1 (el) 2018-02-14
TWI310384B (en) 2009-06-01
JP4381137B2 (ja) 2009-12-09
ECSP034865A (es) 2004-01-28
AU2002304401C1 (en) 2009-03-05
RS52144B (en) 2012-08-31
PA8546301A1 (es) 2003-05-14
CA2448281C (fr) 2009-05-05
WO2002096909A1 (fr) 2002-12-05
US7301023B2 (en) 2007-11-27
MA27029A1 (fr) 2004-12-20
AU2008203170A1 (en) 2008-08-07
KR100926875B1 (ko) 2009-11-16
LTPA2017025I1 (lt) 2017-09-11
KR20060133117A (ko) 2006-12-22
EA007251B1 (ru) 2006-08-25
NZ540332A (en) 2007-05-31
NO20035201L (no) 2003-11-24
AR037321A1 (es) 2004-11-03
CA2448281A1 (fr) 2002-12-05
NO328578B1 (no) 2010-03-22
BR0209246A (pt) 2004-06-15
EA200301193A1 (ru) 2004-04-29
OA12612A (en) 2006-06-09
LUC00031I1 (fr) 2017-08-10

Similar Documents

Publication Publication Date Title
BE2022C531I2 (fr)
BE2022C502I2 (fr)
BE2022C547I2 (fr)
BE2017C057I2 (fr)
BE2017C051I2 (fr)
BE2017C032I2 (fr)
BE2016C051I2 (fr)
BE2015C046I2 (fr)
BE2014C052I2 (fr)
BE2014C036I2 (fr)
BE2014C026I2 (fr)
BE2017C050I2 (fr)
BE2014C004I2 (fr)
BE2014C006I2 (fr)
BE2011C034I2 (fr)
BE2007C047I2 (fr)
AU2002307149A8 (fr)
BRPI0209186B1 (fr)
BE2016C021I2 (fr)
BE2014C008I2 (fr)
BRPI0204884A2 (fr)
CH1379220H1 (fr)
BE2017C059I2 (fr)
BRPI0101486B8 (fr)
BE2012C051I2 (fr)